- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 217/24 - Atomes d'oxygène
Détention brevets de la classe C07D 217/24
Brevets de cette classe: 471
Historique des publications depuis 10 ans
|
30
|
31
|
34
|
24
|
35
|
31
|
21
|
32
|
23
|
16
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Celgene Quanticel Research, Inc. | 163 |
19 |
| Alcon, Inc. | 5493 |
18 |
| Bristol-myers Squibb Company | 4850 |
17 |
| Novartis AG | 10709 |
11 |
| Allergan, Inc. | 2334 |
9 |
| sanofi-aventis | 357 |
9 |
| Boehringer Ingelheim International GmbH | 4648 |
8 |
| Pfizer Inc. | 3391 |
8 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 166 |
7 |
| The University of Queensland | 664 |
7 |
| Genentech, Inc. | 4012 |
6 |
| NHWA Pharma. Corporation | 50 |
6 |
| Resverlogix Corp. | 57 |
6 |
| AstraZeneca AB | 2877 |
5 |
| Arbutus Biopharma Corporation | 177 |
5 |
| BELLUS Health Inc. | 13 |
5 |
| Nerviano Medical Sciences S.r.l. | 256 |
5 |
| Glaxosmithkline Intellectual Property Development Limited | 767 |
4 |
| Astellas Pharma Inc. | 1088 |
4 |
| Cytokinetics, Inc. | 283 |
4 |
| Autres propriétaires | 308 |